Evoq Remedies Ltd Stock Price Today (NSE: EVOQ)
Fundamental Score
Evoq Remedies Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Evoq Remedies Ltd share price today is ₹2.94, up +0.00% on NSE/BSE as of 6 March 2026. Evoq Remedies Ltd (EVOQ) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of ₹7.99 (Cr). The 52-week high for EVOQ share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 4.54x, EVOQ is currently trading below its industry average P/E of 35.45x. The company has a Return on Equity (ROE) of 0.26% and a debt-to-equity ratio of 0.00.
Evoq Remedies Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Evoq Remedies Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Evoq Remedies Share Price Analysis: A Strategic Growth Perspective
One of the most significant challenges in the Trading & Distributors sector is consistently achieving high returns on capital due to thin margins and intense competition. This analysis delves into the financial standing of Evoq Remedies Ltd, focusing on the factors influencing its valuation. Currently, the Evoq Remedies share price sits at ₹3.2699999809265137, with a Price-to-Earnings (PE) ratio of 4.54. This valuation immediately raises questions when compared to the broader market and industry peers.
A key concern is Evoq Remedies' Return on Capital Employed (ROCE) of 0.35%. This exceptionally low ROCE indicates that the company is struggling to generate profits from its invested capital. In terms of competitive advantage, or “moat,” a weak ROCE erodes its foundation. Without substantial improvement, Evoq Remedies could face difficulty attracting investment and sustaining long-term growth. This is especially concerning when contrasted with potentially higher ROCE figures among its peers. A low ROCE also affects the price to earning multiple assigned.
When assessing sector peers, it's crucial to look beyond just the numbers. While
Prismx Global Ventures Ltd might show comparable financial metrics on paper, a qualitative assessment of management quality is paramount. Investors should consider factors such as the experience, track record, and strategic vision of the leadership team at both Evoq Remedies and its competitors. For example, the management skill might play a crucial role in the share price of both entities.Ultimately, the Evoq Remedies share price and its sustainability hinge on its ability to improve its operational efficiency and capital allocation. A low ROCE, as it stands, makes it difficult for the company to build a strong competitive moat and attract long-term investors. This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, and offers an observational perspective on the current financial state of Evoq Remedies Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Evoq Remedies Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EVOQ across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 4.54 vs Industry: 35.45)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (103.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (0.26%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-8.24%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Weak Earnings Growth (-67.52% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-40.33 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (11.21%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Evoq Remedies Ltd Financial Statements
Comprehensive financial data for Evoq Remedies Ltd including income statement, balance sheet and cash flow
About EVOQ (Evoq Remedies Ltd)
Evoq Remedies Ltd (EVOQ) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Trading & Distributors sector with a current market capitalisation of ₹7.99 (Cr). Evoq Remedies Ltd has delivered a Return on Equity (ROE) of 0.26% and a ROCE of 0.35%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking EVOQ share price can monitor key metrics including P/E ratio, promoter holding of 11.21%, and quarterly earnings growth.
Company Details
Key Leadership
Latest News
EVOQ Share Price: Frequently Asked Questions
What is the current share price of Evoq Remedies Ltd (EVOQ)?
As of 06 Mar 2026, 09:59 am IST, Evoq Remedies Ltd share price is ₹2.94. The EVOQ stock has a market capitalisation of ₹7.99 (Cr) on NSE/BSE.
Is EVOQ share price Overvalued or Undervalued?
EVOQ share price is currently trading at a P/E ratio of 4.54x, compared to the industry average of 35.45x. Based on this relative valuation, the Evoq Remedies Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of EVOQ share price?
The 52-week high of EVOQ share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Evoq Remedies Ltd share price?
Key factors influencing EVOQ share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Evoq Remedies Ltd a good stock for long-term investment?
Evoq Remedies Ltd shows a 5-year Profit Growth of N/A% and an ROE of 0.26%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in EVOQ shares.
How does Evoq Remedies Ltd compare with its industry peers?
Evoq Remedies Ltd competes with major peers in the Trading & Distributors. Investors should compare EVOQ share price P/E of 4.54x and ROE of 0.26% against the industry averages to determine competitive standing.
What is the P/E ratio of EVOQ and what does it mean?
EVOQ share price has a P/E ratio of 4.54x compared to the industry average of 35.45x. Investors pay ₹5 for every ₹1 of annual earnings.
How is EVOQ performing according to Bull Run's analysis?
EVOQ has a Bull Run fundamental score of 20.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does EVOQ belong to?
EVOQ operates in the Trading & Distributors industry. This classification helps understand the competitive landscape and sector-specific trends affecting Evoq Remedies Ltd share price.
What is Return on Equity (ROE) and why is it important for EVOQ?
EVOQ has an ROE of 0.26%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Evoq Remedies Ltd generates profits from shareholders capital.
How is EVOQ debt-to-equity ratio and what does it indicate?
EVOQ has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is EVOQ dividend yield and is it a good dividend stock?
EVOQ offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Evoq Remedies Ltd shares.
How has EVOQ share price grown over the past 5 years?
EVOQ has achieved 5-year growth rates of: Sales Growth 5.33%, Profit Growth N/A%, and EPS Growth -67.52%.
What is the promoter holding in EVOQ and why does it matter?
Promoters hold 11.21% of EVOQ shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Evoq Remedies Ltd.
What is EVOQ market capitalisation category?
EVOQ has a market capitalisation of ₹8 crores, placing it in the Small-cap category.
How volatile is EVOQ stock?
EVOQ has a beta of N/A. A beta > 1 suggests the Evoq Remedies Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is EVOQ operating profit margin trend?
EVOQ has a 5-year average Operating Profit Margin (OPM) of -8.24%, indicating the company's operational efficiency.
How is EVOQ quarterly performance?
Recent quarterly performance shows Evoq Remedies Ltd YoY Sales Growth of N/A% and YoY Profit Growth of 103.09%.
What is the institutional holding pattern in EVOQ?
EVOQ has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Evoq Remedies Ltd stock.